Increasing Accessibility to Psychedelic Medicine
Log in To Watch the Recording
*Exclusive for members.
Thursday, February 29th at 5 pm Pacific, 8 pm Eastern >> Log in to Watch the Recording >>
An EXCLUSIVE Panel Discussion For Members Of The Psychedelic Medicine Association:
Increasing Accessibility to Psychedelic Medicine
Panel Moderator:
Lynn Marie Morski, MD, JD
President, Psychedelic Medicine Association
Panelists:
Richard Nockowitz, MD
Chief Medical Officer, TARA Mind
Dr. Richard Nockowitz is the Chief Medical Officer of TARA Mind and brings 30 years of clinical and business experience to the role.
Dr. Nockowitz is a board-certified psychiatrist who received his medical training at Albert Einstein College of Medicine and then psychiatric training at Harvard Medical School’s Massachusetts General Hospital, where he was also a Consultation Psychiatry/Psychosomatic Medicine Fellow. With expertise in all aspects of general psychiatry and psychopharmacology, as well as neuropsychiatry, the medical-psychiatric interface, addiction medicine, and patient compliance, he has focused his clinical practice on providing consultation and guidance on complex diagnostic cases and refractory psychiatric conditions. He has authored numerous book chapters on depression and suicide, psychopharmacology, and enhancing patient compliance, and is a national lecturer to medical audiences on various psychiatric conditions and their treatment.
Dr. Nockowitz is the Founder and President of My Psychiatric Partner, LLC, a national telepsychiatry company, as well as of My Psychiatric Mentor, LLC, a subsidiary of My Psychiatric Partner, which will offer a unique, online advanced clinical training course in psychiatric practice for mental health nurse practitioners. Dr. Nockowitz has years of leadership experience that range from running clinical departments at academic medical centers to Medical Director roles in diverse treatment settings caring for all patient populations, including designing and implementing psychiatry services for Amwell, one of the country’s largest telepsychiatry companies.
After decades of clinical practice, Dr. Nockowitz is convinced that there is a limit to what traditional treatments can offer many patients struggling with mental health issues, and that there is a desperate need for better solutions. As a student of the history of psychedelics, their clinical applications, and the decades of clinical research in the field, he is invigorated by the long-delayed opportunity to make safe, psychedelic-based solutions accessible to patients around the world through his work with TARA Mind.
Reverdi Darda, RN, BScN, CHE
Administrative Advisor, ATMA Journey
Reverdi one of the Administrative Advisors of ATMA Journey. With over 30 years of experience as a Registered Nurse her experience and expertise in the areas of community engagement, planning, project and change management have significantly impacted outcomes of numerous projects that she has been involved in. She understands the challenges that healthcare systems and their structures have in offering consistent, reliable, client focused services and she is passionate about bringing evidence-based innovation forward to those in need.
Reverdi is Metis and a direct descendant of Damase Carriere who fought against Canadian Colonialism beside Louis Riel in the heroic Metis North-West Resistance of 1885. Her passion to engage communities and work together for the equity and inclusion of all is reflective in her family’s legacy.
Her professional career includes Executive leadership roles in the public, government, and non-profit sectors. She currently sits on the board of MAPS Canada, has a passion for life long learning and easily unites individuals to achieve common objectives, goals, and outcomes.
Kyle Buller
Co-Founder and VP of Education & Training, Psychedelics Today
Kyle has earned his B.A. in Transpersonal Psychology and his M.S. in Clinical Mental Health Counseling with an emphasis in Somatic Psychology from Prescott College. Kyle is a Licensed Associate Counselor and offers psychotherapy services specializing in psychedelic integration, spiritual emergence, and ketamine-assisted psychotherapy. Kyle’s clinical background in mental health consists of working with at-risk teenagers in crisis and with individuals experiencing an early episode of psychosis and providing counseling to undergraduate/graduate students in a university setting.
As MDMA approaches (likely) FDA approval and ketamine-assisted therapy use expands, the question of how psychedelic therapies will be integrated into our mainstream medical model persists – as does the most important follow-up question: how will we make these life-changing therapies accessible to those who need them?
While researchers are hard at work figuring out the indications and contraindications for the different forms of psychedelic medicine, it is imperative to start working toward ensuring that psychedelic options are available to those who most need them – which is often the same people who are often left out by the shortcomings of our current healthcare system.
We know that psychedelics have shown great promise in treating trauma-based conditions, but that will be of little help if those patients who are the most traumatized, like our veterans and those who have survived the trauma associated with racism and poverty, are unable to afford psychedelic care.
This month we are truly fortunate to have panelists who have spent an immense amount of time working on ways to make psychedelic healing more accessible. They’ll be discussing the following:
- An initiative is dedicated to increasing the accessibility of psychedelic medicines, with a specific focus on smaller urban centers
- Tackling health equity barriers that prevent individuals from receiving effective mental health care
- How certain forms of breathwork can attain an altered state which can help expand access to those who can’t afford or who may not be medically cleared to take psychedelics
…and much more!
As always, there will be ample time for audience Q & A, so you’ll get to interact with the panelists directly!
So please join us for this live panel discussion on Thursday, February 29th at 5 pm Pacific, 8 pm Eastern. This is exclusively for members of the Psychedelic Medicine Association, so if you have not yet registered, please do so here. A link to the recording will be available afterward if you cannot make it to the live event.
Hope to see you all on the 29th!